In addition, this paper aims to establish the guidelines for rectal cancer treatment regarding COX-2 expression levels and determine the utility of the assessment of COX-2 expression while predicting the treatment response in patients with rectal cancer who are undergoing preoperative radiotherapy or chemoradiotherapy. The gene discussed is PTGS2; the disease is rectal cancer.